When patients present with resistant hypertension, clinicians aim to stabilize blood pressure by adding or replacing traditional agents, then hope that noncompliance and reduced adherence won’t further complicate management. Fortunately, new and effective pharmacologic treatments, device therapies and multidisciplinary team approaches are rapidly changing outcomes. This CE-certified symposium will assess diagnostic delay consequences, traditional treatment shortfalls, dual endothelin-receptor antagonists and why guidelines don’t keep pace with real-world clinical practice.